Literature DB >> 2971839

Changes of molecular forms of atrial natriuretic peptide after treatment for congestive heart failure.

F Marumo1, T Kurosawa, S Takeda, Y Katoh, N Hasegawa, K Ando.   

Abstract

In the present study, an attempt was made to clarify whether ANP molecular forms in the plasma of severe congestive heart failure patients differ from those in healthy persons and whether ANP molecular forms in the plasma of the patients were changed by successful treatment of cardiac disease. Twenty patients with congestive heart failure were treated at Kitasato University Hospital. They were classified as class III or IV by New York Heart Association criteria at the time of admission. Plasma ANP concentrations decreased after treatment from 356 +/- 58.2 to 72.3 +/- 14.8 pg/ml. The gel permeation chromatograms from the plasma of healthy persons showed low, or low and high molecular weight ANP peaks which correspond to the elution positions of authentic alpha-ANP or ribonuclease A (mol. wt., 13.7 kdalton). In patients with severe congestive heart failure at a severe stage, middle molecular weight ANP consisted with the elution position of authentic beta-ANP was particularly noted in addition of low and high molecular weight ANP peaks. This middle molecular weight peak disappears in most of cases by successful treatment. Molecular forms in the plasma obtained from the coronary sinus and the inferior or superior vena cava were essentially the same. These results indicate that the middle molecular weight ANP supposed as beta-ANP may particularly be secreted in severe congestive heart failure patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971839     DOI: 10.1007/bf01726925

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Augmented synthesis of beta-human atrial natriuretic polypeptide in human failing hearts.

Authors:  A Sugawara; K Nakao; N Morii; T Yamada; H Itoh; S Shiono; Y Saito; M Mukoyama; H Arai; K Nishimura
Journal:  Biochem Biophys Res Commun       Date:  1988-01-15       Impact factor: 3.575

2.  Plasma levels of atrial natriuretic factor in patients with congestive heart failure.

Authors:  H Nakaoka; K Imataka; M Amano; J Fujii; M Ishibashi; T Yamaji
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

3.  Plasma atrial natriuretic peptide concentrations in the recovery period of myocardial infarction in arterial and venous blood samples.

Authors:  D H Petzl; E Hartter; W Osterode; H Böhm; W Woloszcuk; E Schuster
Journal:  Horm Metab Res       Date:  1986-07       Impact factor: 2.936

4.  Atrial natriuretic peptide in Bartter's syndrome.

Authors:  K Yamada; K Tajima; K Moriwaki; S Tarui; A Miyata; K Kangawa; H Matsuo
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

5.  Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).

Authors:  K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

6.  Raised circulating levels of atrial natriuretic peptides in essential hypertension.

Authors:  G A Sagnella; N D Markandu; A C Shore; G A MacGregor
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

7.  Rat atrial natriuretic factor: complete amino acid sequence and disulfide linkage essential for biological activity.

Authors:  K S Misono; H Fukumi; R T Grammer; T Inagami
Journal:  Biochem Biophys Res Commun       Date:  1984-03-15       Impact factor: 3.575

8.  Molecular forms of atrial natriuretic polypeptides circulating in human plasma.

Authors:  A Miyata; T Toshimori; T Hashiguchi; K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1987-01-30       Impact factor: 3.575

9.  Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure.

Authors:  T Eisenhauer; J Talartschik; F Scheler
Journal:  Klin Wochenschr       Date:  1986

10.  Molecular weight heterogeneity of plasma-ANF in cardiovascular disease.

Authors:  R M Arendt; A L Gerbes; D Ritter; E Stangl
Journal:  Klin Wochenschr       Date:  1986
View more
  2 in total

1.  Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide.

Authors:  Uzoma N Ibebuogu; Inna P Gladysheva; Aiilyan K Houng; Guy L Reed
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

Review 2.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.